Table 1.
In vitro activity of moxifloxacin against potential Gram-positive and Gram-negative aerobic pathogens in SSSIs
| Organism | Isolates (n) | Range of MIC90s (mg/L) | References |
|---|---|---|---|
| Staphylococcus aureus | 1427 | 0.03–C>4.0 | (1–C6) |
| methicillin-sensitive | 1221 | 0.06–4.0 | (7–21, 27) |
| methicillin-resistant | 1036 | 2–16 | (2, 7–12, 14–21) |
| S. epidermidis | 183 | 0.06–4.0 | (3, 5, 18, 20) |
| methicillin-sensitive | 424 | 0.06–2.0 | (9–12, 15–17, 19, 22) |
| methicillin-resistant | 641 | 0.12–>8.0 | (9–12, 14–17, 19, 27) |
| Group A streptococci | 1882 | 0.12–0.50 | (2,6–9,11,13,15, 18–20, 23–25) |
| Group B streptococci | 139 | 0.12–0.50 | (6, 9, 11, 15, 18, 19, 23) |
| Enterococcus faecalis | 438 | 0.25–16 | (2, 6, 9, 11, 13–15, 18–23, 27) |
| E. faecium | 263 | 2–≥32 | (6, 9, 11, 13–15, 18, 20, 23, 27) |
| Escherichia coli | 795 | 0.015–1.0 | (2, 13–16, 18, 19, 22, 26, 27) |
| Klebsiella pneumoniae | 619 | 0.031–1.0 | (2, 14–16, 18, 19, 27) |
| Citrobacter freundii | 290 | 1–4 | (11, 14–16, 18, 19, 22, 27) |
| Morganella morganii | 248 | 0.13–16 | (11, 14–16, 18–20) |
| Proteus mirabilis | 530 | 0.25–16 | (2, 11, 14–16, 18–22, 27) |
| Enterobacter cloacae | 541 | 0.06–2 | (11, 14–16, 18, 19, 27) |
| E. aerogenes | 325 | 0.5–<16 | (11, 14–16, 18, 19, 27) |
| Pseudomonas aeruginosa | 2376 | 4–64 | (2, 11, 13, 15, 16, 18– 22, 27) |
| P. vulgarus | 141 | 0.25–1 | (11, 15, 16, 18, 20, 22) |
| Acinetobacter calcoaceticus | 60 | 0.06–1 | (2, 11, 22) |
Abbreviations: MIC90, minimum inhibitory concentration for 90% of isolates.
Note: For entries with multiple studies, data are the range.To be included, studies had to have a minimum of 10 isolates of the microorganism-of-interest, use a National Committee for Clinical Laboratory Standards - approved methodology, and an inoculum of 104–106 organisms.
References:1, Stratchounski et al 2005; 2, Blondeau et al 2000; 3, Jacobs et al 2004; 4, Goldstein et al 2000; 5, Goldstein et al 1997; 6, Malathum et al 1999; 7, Bowker et al 2003; 8, Noviello et al 2003; 9, Speciale et al 2002; 10, von Eiff et al 1999; 11, Bauernfeind 1997; 12, Patel et al 2004; 13,Wenzler et al 2004; 14, Edmiston et al 2004; 15, Fung-Tomc et al 2000; 16, Milatovic et al 2000; 17, Hardy et al 2000; 18, Barry et al 1999; 19, Fass 1997; 20,Woodcock et al 1997; 21, Bogdanovich et al 2005; 22, Dalhoff et al 1996; 23, Hoogkamp-Korstanje et al 2000; 24, Hsueh et al 2003; 25, Amabile-Cuevas et al 2001; 26, Blondeau 2002; 27, Edmiston et al 2005.